We are led by an experienced management team with a proven track record of developing scientific and medical products and bringing them to market.
Our Executive Committee assists the Chairman and CEO in our strategic and operational management. Our Executive Committee has the support of the Directors’ Committee, which is the instance of operational review of our projects. Our Directors’ Committee consists of our Executive Committee members and our key managers. Our Directors’ Committee endorsed our annual objectives of the Company.
Dr. Pierre-Henri Benhamou
Dr. Pierre-Henri Benhamou co-founded DBV Technologies in 2002, and has served as Chief Executive Officer from 2002 to the present and Chairman of board of directors since initial public offering on NYSE Euronext Paris in March 2012. With Pr. Christophe Dupont and Bertrand Dupont, he described for the first time and patented the epicutaneous method of immunotherapy and explored with the scientific team the wide range of applications of the method. Dr. Benhamou is a physician, specializing in pediatric gastroenterology. He has held numerous clinical and academic positions. He received the Altran Foundation Prize for Innovation in 2003 for his work on the development of diagnostic patch tests. Dr. Benhamou has published numerous papers and originated key scientific collaborations for us and has been instrumental in forming the Scientific Advisory Board. Dr. Benhamou holds an MD. in Medicine from Faculté de Médecine de Paris in 1984 and his specialization degree in Pediatrics in 1987. The board of directors believes that Dr. Benhamou’s leadership, deep knowledge of the company and scientific experience will allow him to drive DBV to the success.
Bertrand Dupont previously Chief Technical Officer has been appointed Senior Executive Vice President Technology since January 2015, and will be in charge of the continued development of the electrospray and upscaling of the production tools. He is a member of the Executive Committee.
From 1977 to 2002, Mr. Bertrand has served as a professor at the high school and at the university, teaching mechanics and robotics. In 1996, Mr. Dupont began to put his skills and expertise to use in biomedical research. Since 2000, he has been at the core of the development of the Viaskin® patches and applications. As Chief Industrial Officer, Mr. Dupont is a key figure in the development of the Viaskin® technology and the application systems. He is responsible for every technical development around the Viaskin® technology: design of the Viaskin® patch, in-house industrial patch filling processes, design and building of the machines which are developed by DBV Technologies. He is also responsible for the production of the finished product in the facilities of the CMO DBV partners. Mr. Dupont received an engineering degree from the School of Arts et Métiers of Paris in 1974 and an Aggregation in mechanical engineering in 1987.
David Schilansky has served as Chief Financial Officer since December 2011 and has been appointed as Chief Operating Officer in January 2015 to support the CEO in the implementation of DBV’s strategy. He supervises all financial work, human resources, general secretary, communication, investor relations as well as partnership and business development activities. He is a member of the Executive Committee.
From 2006 to 2011, Mr. Schilansky held various important positions at the Ipsen Group, or Ipsen, including Interim Chief Financial Officer, Deputy Chief Financial Officer, member of Ipsen’s Executive Committee and other positions in the administration and finance department and participated in various external growth operations and creation of Ipsen’s investor relations function. From 2003 to 2006, Mr. Schilansky spent three years at Thomson Inc. (now Technicolor S.A.) as co-head of investor relations. From 1999 to 2002, he spent three years at Warburg Dillon Read (now UBS Investment Bank) in the field of mergers and acquisitions. Mr. Schilansky received a Master degree from Université de Paris Dauphine and a Master degree from Imperial College in London.
Mr. Charles Ruban has been Chief Commercial Officer since January 20, 2016. Mr. Ruban served as Senior Executive Vice President of Clinical Development & North American Operations since January 2015 until January 20, 2016. Charles Ruban has served as Chief Development Officer since June 2012 and oversees all development activities including clinical operations, medical affairs, non clinical development, regulatory affairs and pharmaceutical development. He is a member of the Executive Committee. From 2003 to 2012, Mr. Ruban held various executive positions at Stallergènes S.A., including Senior Vice President of Product Development, member of the Executive Committee, Director of Research & Development Program and Director of Supply Chain. From 1994 to 2003, Mr. Ruban spent nine years at Eurogroup Consulting as a management consultant. Mr. Ruban received an Engineering degree from the Ecole Centrale de Lyon, trained at Harvard-MIT Division of Health Sciences and Technology for his Master of Science in Biomedical Engineering and graduated with an Executive MBA from INSEAD.
PharmD from the Université René Descartes in Paris with an M.B.A. from IAE Paris Sorbonne and a Master of Law in Public Health from the faculty of Sceaux, Laurent Martin joined DBV Technologies with more than 15 years of experience in the pharmaceutical industry. He has extensive experience in the management of international pharmaceutical development projects in Europe and the United States and in marketing authorization applications, particularly in Europe with the European Medicines Agency (EMA) via the centralized procedure. He acquired his expertise in regulatory affairs through various pharmaceutical companies, such as Galderma, Guerbet, and finally, Orphan Europe, a company specialized in the development and marketing of orphan drugs, in which his last position was as Interim Responsible Pharmacist (Qualified Person), Manager of Pharmaceutical and Pre-Clinical Development, and Quality Assurance Manager. Mr Laurent Martin has been Chief Development Officer since January 20, 2016. He elaborates all the regulatory strategy of the products being developed, coordinates the regulatory filings related to the clinical studies and the international registration of the drugs of DBV Technologies. He is also Director of Quality.
With a Doctorate in Pharmacology from the Université Pierre et Marie Curie in Paris and an Executive M.B.A. from the ESCP, the European School of Management based in Paris, in the past, Wence Agbotounou held project management positions in several global, highly reputed contract research organizations (CROs), such as Quintiles and PRA International. As a Project Manager and then Project Director of International Clinical projects, he launched and led successfully on a global scale Phase II and III clinical trials and clinical programs in Asthma and Allergy for numerous medium- and large-scale pharmaceutical laboratories, including several pivotal Phase III trials in immunotherapy. Wence is a member of the Directors’ Committee.
Pascale Ehouarn joined DBV in 2006, she participates in the development of Viaskins® processes and the design of production machinery, she is also responsible for the manufacture of pharmaceutical patches for allergy desensitization.
With a PhD in Plasma Physics from the University of Paris XI, she completed her thesis and then did a valuation study at Supélec on the electrospray process of water assisted by electrical discharges, in collaboration with EDF. Pascale also completed a post-doctorate at the University of Karlsruhe in Germany, on the packaging of nanopowders by shock, in partnership with BASF. She then secured a position as an R&D Project Manager, France Unaxis, Displays Division, in charge of particulate contamination control in production systems by plasma deposition of thin films by PECVD and PVD sites in Taiwan. Pascale is a member of the Directors’ Committee.
Lucie Mondoulet obtained a biochemical and food engineering degree from the Institut National des Sciences Appliqués [National Institute of Applied Sciences, "INSA,” Toulouse] before specializing in the field of food allergies. Her doctorate was completed at the Institut National de la Recherche Agronomique [French National Institute for Agricultural Research, "INRA"] in the immunology and food allergies unit, in which she studied the biochemical composition of peanut allergens and the effects of heat and enzymatic treatments on the allergenicity of peanut allergens. Her specialization was continued with one year of post-doctoral work at the Centre National de la Recherche Scientifique [French National Centre for Scientific Research, "CNRS"] in Paris in the Department of Allergies and the Environment, where she was responsible for the purification of pollen allergens and the study of the repertoire of immunological responses among allergy patients. A member of the research staff of DBV Technologies as a research engineer first of all, she refined all the pre-clinical models (pharmacology) necessary for the characterization of the products of the Company before assuming responsibility for the coordination of the research staff, under the responsibility of PH Benhamou. Her research work has been the object of numerous reports in national and international conferences, publications in reviewed scientific journals, and patents. Lucie is a member of the Directors’ Committee.
Susanna Mesa manages the day-to-day operations of DBV Technologies, Inc., DBV’s US subsidiary. In collaboration with the rest of the management team, Susanna is also responsible for executing DBV’s global investor relations and strategy programs. She joined DBV Technologies from the Trout Group, a leading investor relations and financial advisory firm serving the life sciences and clean technology industries, where she focused on expanding clients’ shareholder base and facilitating access to capital. Prior to Trout, Susanna worked for the corporate development arm of the Leukemia and Lymphoma Society and at the US investment bank, Jefferies. She graduated Magna Cum Laude from the University of Georgia in Athens.
Nathalie Donne holds a degree in biology from the University of Paris VI France (Master of advanced studies in Cardiovascular Pharmacology) and a Master's degree in biotechnology innovation from the Institut National Agronomique de Paris and Reims Management School (MASTERNOVA). She then became product manager at DBV technologies from 2003 to 2006, where she first worked on the Diallertest® Milk product, then became project manager in immunotherapy from 2006 to 2009. Since 2009, Nathalie participates in the Partnership and Business Development activities as well as building projects for French & worldwide public grants. Nathalie is a member and secretary of the Directors’ Committee.
Claude Thébault holds an MD in Medicine from Paris V University, a master’s degree in biological & medical sciences, with an extensive background in medical science and R&D acquired during her 20+ years’ experience in Pharmaceutical Industry, she joined DBV Technologies as Medical Director. Dr. Thébault started at headquarter Rhône Poulenc Rorer as an international Biostatistician Manager. She then obtained a Post-doc University diploma (DIU) on Sleep Disorders including Respiratory Diseases and was involved in many clinical studies in asthma & allergy. During the first 9 years inside Rhône-Poulenc Rorer, she held various positions, including one as international Physician Manager on Allergy products. She also worked as European Clinical Development Manager, Vaccine division, for Aventis Pasteur MSD and was a primary leadership force of R&D Department operations and projects for ALTANA Pharma’s Respiratory and Gastroenterology lines. Prior to joining, during seven years, she provided decisive leadership and direction for Medical Affairs of Roche and Besins Healthcare’s Operations. Claude is a member of the Director’ Committee.